In addition to Joseph T. McMahon, profiled under Management, the KBI Biopharma Board of Directors includes:

Howard F. Auman, Jr.
Chairman
Mr. Auman is an accomplished entrepreneur, owner of Southern Property Management LLC, Auman Productions LLC and Partner and Board member of Blue Highways Television Network. He builds, owns and manages commercial buildings and apartment complexes throughout central North Carolina. Previously, he served on the board of Triad Bank, the Board of Trustees of Randolph Community College and as President of the Asheboro Home builders Association. He is a graduate of the University of North Carolina at Chapel Hill.

James T. Hoover
Mr. Hoover is co-founder and managing partner of IDM Partners, a private venture firm that has provided development and management support to proven entrepreneurs since 1987. He is also Principal and Director of Uplink Corp., Cedar Creek Companies, Chairman of Avatar Technology Inc., and partner in iMagine Ventures, Ltd.

Harrington Bischof
Mr. Bischof is co-founder and president of Pandora Capital Corp., a private investment company. He has thirty years of investment banking experience, including 11 years with White, Weld & Co., where he became Senior Vice President and head of its investment banking activities in the Midwest. Following the merger of White, Weld and Co. with Merrill Lynch & Co., he served on several Merrill Lynch Investment Banking management committees and as a Director of Merrill Lynch International Bank in London. Mr. Bischof later served as Senior Advisor to Prudential Securities, Inc. He is currently a Director of Peerless Industrial Group, Inc., Old Republic International Corporation (NYSE) and Utilities, Inc.

John Jeppson
Mr. Jeppson has spent 25 years consulting dynamic small businesses. His practice has helped more than 100 companies achieve success. He is a founding director of The Vanguard Group, Inc. He joined the KBI Biopharma team in 1997, and served as COO and CEO until fourth quarter 2001. He earned B.A. and J.D. degrees from Harvard University.

If you have an inquiry regarding investor relations, click here to send an email to IR@kbibiopharma.com